US · CLDX
Celldex Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Hampton, NJ 08827
- Website
- celldex.com
Price · as of 2025-12-31
$32.31
Market cap 2B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $30.82 | -4.61% |
| Intrinsic Value(DCF) | $13.85 | -57.13% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $260.95 | +707.64% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $58.50 | $450.47 | $11.31 | $0.00 | $1,166.71 |
| 2012 | $184.80 | $74.83 | $8.39 | $0.00 | $0.00 |
| 2013 | $380.40 | $157.78 | $41.25 | $0.00 | $805.20 |
| 2014 | $446.10 | $178.44 | $12.49 | $0.00 | $81.49 |
| 2015 | $52.20 | $20.88 | $21.91 | $0.00 | $0.00 |
| 2016 | $52.05 | $20.82 | $15.51 | $0.00 | $0.00 |
| 2017 | $42.30 | $23.51 | $8.78 | $0.00 | $0.00 |
| 2018 | $5.10 | $5.78 | $0.00 | $0.00 | $231.28 |
| 2019 | $2.50 | $25.43 | $1.75 | $0.00 | $181.49 |
| 2020 | $25.38 | $38.94 | $4.40 | $0.00 | $0.00 |
| 2021 | $31.16 | $31.74 | $7.59 | $1.56 | $45.47 |
| 2022 | $41.80 | $35.13 | $3.98 | $0.00 | $93.72 |
| 2023 | $47.91 | $51.86 | $5.12 | $0.00 | $0.00 |
| 2024 | $20.67 | $22.47 | $7.89 | $0.00 | $0.00 |
| 2025 | $30.00 | $30.82 | $3.08 | $0.00 | $260.95 |
AI valuation
Our deep-learning model estimates Celldex Therapeutics, Inc.'s (CLDX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $30.82
- Current price
- $32.31
- AI upside
- -4.61%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$13.85
-57.13% upside
Graham-Dodd
—
— upside
Graham Formula
$260.95
+707.64% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CLDX | Celldex Therapeutics, Inc… | $32.31 | 2B | -5% | -57% | — | +708% | -7.71 | 3.78 | 1330.00 | -5.79 | -13.03 | 3.99 | 100.00% | -19160.00% | -17253.33% | -40.62% | -1576.31% | -37.63% | 0.00 | — | 10.49 | 10.21 | 0.10 | 5918.00% | -7863.00% | 3379.00% | -10.71% | -4.14 | -1171.86% | 0.00% | 0.00% | 0.10% | -5.15 | -6.92 | 985.84 | 16.46 |
| ABCL | AbCellera Biologics Inc. | $3.61 | 1.08B | +1,038% | -58% | -83% | — | -7.79 | 1.18 | 15.19 | -5.71 | — | 1.30 | 100.00% | -288.98% | -194.88% | -14.47% | -29.60% | -10.78% | 0.29 | — | 11.32 | 9.21 | -0.98 | -1091.00% | 16056.00% | -689.00% | -15.25% | -2.04 | -28.78% | 0.00% | 0.00% | 0.00% | -4.09 | -5.10 | 11.82 | 2.19 |
| BHVN | Biohaven Ltd. | $11.52 | 1.22B | — | — | — | — | -3.22 | 6.43 | — | -2.59 | -5.20 | 6.75 | 0.00% | — | — | -198.83% | -3466.81% | -150.03% | 0.09 | — | 3.49 | 3.17 | 0.07 | 6195.00% | — | 7519.00% | -21.53% | -3.78 | -2297.22% | 0.00% | 0.00% | 0.00% | -2.57 | -3.88 | — | 1.47 |
| HRMY | Harmony Biosciences Holdi… | $28.54 | 1.64B | +155% | +609% | +1% | +178% | — | 1.91 | 1.91 | 4.41 | — | 2.13 | 77.16% | 24.00% | 18.27% | 0.00% | 43.46% | 0.00% | 0.28 | 14.23 | 3.60 | 3.46 | -2.01 | 797.00% | 2151.00% | 5909.00% | 20.94% | 1.38 | 98.30% | 0.00% | — | 14.52% | 5.40 | 3.24 | 1.30 | 4.50 |
| IMNM | Immunome, Inc. | $21.86 | 2B | +132% | -83% | — | +492% | -1.87 | 3.02 | 60.58 | -2.21 | — | 3.02 | 100.00% | -3382.37% | -3240.38% | -194.63% | 1276.40% | -150.71% | 0.03 | — | 4.08 | 4.00 | 0.92 | -706.00% | -3550.00% | 185621.00% | -30.00% | -2.04 | 685.79% | 0.00% | 0.00% | 7.58% | -1.10 | -2.04 | 37.08 | -0.77 |
| JANX | Janux Therapeutics, Inc. | $13.61 | 818.61M | +171% | -7% | -80% | — | — | 0.87 | 83.16 | 0.99 | — | 0.87 | 79.71% | -1576.67% | -1576.67% | 0.00% | -954.78% | 0.00% | 0.02 | — | 39.04 | 38.67 | 0.27 | 4297.00% | -555.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 0.00% | 0.72 | — | -11.28 | 11.29 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| QURE | uniQure N.V. | $15.63 | 962.87M | +52% | -69% | — | — | -2.48 | -88.12 | 21.94 | -1.83 | — | -5.94 | 32.42% | -679.58% | -883.35% | -238.46% | 63.55% | -34.51% | -9.78 | -2.89 | 9.74 | 9.32 | 0.58 | -2396.00% | 7117.00% | 2157.00% | -31.28% | -4.56 | 64.17% | 0.00% | 0.00% | 0.00% | -1.59 | -1.58 | 10.82 | -2.50 |
| SION | Sionna Therapeutics, Inc. | $36.54 | 1.63B | — | — | — | — | -11.64 | -4.39 | — | -8.30 | -37.90 | -4.39 | 0.00% | — | — | 44.29% | 31.75% | -51.90% | -0.06 | — | 14.49 | 14.16 | 0.40 | 3071.00% | — | 1785.00% | -7.36% | -5.07 | 23.77% | 0.00% | 0.00% | 0.00% | -8.22 | -10.98 | — | -0.48 |
| SYRE | Spyre Therapeutics, Inc. | $43.01 | 2.6B | — | — | — | — | -94.74 | 20.56 | — | -66.55 | — | 20.56 | 0.00% | — | — | -25.17% | 331.08% | -22.39% | 0.00 | — | 13.25 | 12.89 | 0.41 | -3774.00% | — | 752.00% | -1.15% | -2.88 | 267.42% | 0.00% | 0.00% | 0.00% | -66.55 | -82.40 | — | 139.24 |
| VERA | Vera Therapeutics, Inc. | $40.79 | 2.86B | — | — | — | — | -8.67 | 4.29 | — | -6.55 | -12.48 | 4.29 | 0.00% | — | — | -50.71% | 1508.68% | -43.10% | 0.13 | — | 13.64 | 13.37 | 0.93 | 6945.00% | — | 7820.00% | -9.31% | -4.51 | 1156.04% | 0.00% | 0.00% | 9.22% | -6.21 | -8.10 | — | 10.20 |
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
- CEO
- Anthony S. Marucci
- Employees
- 186
- Beta
- 1.21
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($13.85 ÷ $32.31) − 1 = -57.13% (DCF, example).